Mizuho Securities Usa adds Relypsa Inc (RLYP) to its portfolio

Relypsa Inc (RLYP) : Mizuho Securities Usa added new position in Relypsa Inc during the most recent quarter end. The investment management firm now holds 219,600 shares of Relypsa Inc which is valued at $7,042,572 , the company said in a statement filed on Jul 20, 2016 with the SEC.Relypsa Inc makes up approximately 1.28% of Mizuho Securities Usa’s portfolio.

Other Hedge Funds, Including , Marcus Capital sold out all of its stake in RLYP during the most recent quarter. The investment firm sold 65,650 shares of RLYP which is valued $1,319,565.Simplex Trading boosted its stake in RLYP in the latest quarter, The investment management firm added 2,966 additional shares and now holds a total of 18,613 shares of Relypsa Inc which is valued at $374,121. Relypsa Inc makes up approx 0.05% of Simplex Trading’s portfolio.Cutler Group Lp boosted its stake in RLYP in the latest quarter, The investment management firm added 16,986 additional shares and now holds a total of 18,596 shares of Relypsa Inc which is valued at $371,734. Relypsa Inc makes up approx 0.03% of Cutler Group Lp’s portfolio. Bnp Paribas Arbitrage Sa added RLYP to its portfolio by purchasing 1,478 company shares during the most recent quarter which is valued at $29,811.

Relypsa Inc opened for trading at $19.98 and hit $20.43 on the upside on Wednesday, eventually ending the session at $20.1, with a gain of 1.31% or 0.26 points. The heightened volatility saw the trading volume jump to 12,48,955 shares. Company has a market cap of $899 M.

On the company’s financial health, Relypsa Inc reported $-1.26 EPS for the quarter, beating the analyst consensus estimate by $ 0.18 according to the earnings call on May 4, 2016. Analyst had a consensus of $-1.44. The company had revenue of $12.40 million for the quarter, compared to analysts expectations of $7.10 million. During the same quarter in the previous year, the company posted $-0.78 EPS.

Many Wall Street Analysts have commented on Relypsa Inc. H.C. Wainwright Downgraded Relypsa Inc on Jul 22, 2016 to ” Neutral”, Price Target of the shares are set at $32.Relypsa Inc was Upgraded by Morgan Stanley to ” Equal-Weight” on Jul 22, 2016. Relypsa Inc was Downgraded by Brean Capital to ” Hold” on Jul 21, 2016.

Relypsa Inc. is a biopharmaceutical company focused on the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal cardiovascular and metabolic diseases. The Company’s lead product candidate Patiromer for Oral Suspension (Patiromer FOS) is for the treatment of hyperkalemia a life-threatening condition defined as abnormally elevated levels of potassium in the blood. Its New Drug Application (NDA) for Patiromer FOS was accepted for filing by the United States Food and Drug Administration or FDA. The Company’s NDA is supported by a clinical development program consisting of eight clinical trials: three Phase I trials four Phase II trials and one two-part Phase III trial conducted under a Special Protocol Assessment or SPA. The active ingredient is a cross-linked polymeric bead with a calcium containing counterion. The Company has the global royalty-free commercialization rights to Patiromer FOS.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *